11st Department of Neurology,
2Department of Neurology,
3Department of Nursing,
Correspondence Address: Dr. Vasilios C. Constantinides, 1st Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Eginition Hospital,72 Vas. Sofias Ave, Athens 11528, Greece. E-mail: email@example.com ; firstname.lastname@example.org
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy and dementia with Lewy bodies are the most common causes of atypical Parkinsonism and enter the differential diagnosis of Parkinson’s disease. multiple system atrophy, dementia with Lewy bodies and Parkinson’s disease are synucleinopathies, whereas progressive supranuclear palsy and corticobasal degeneration are tauopathies. Multiple cerebrospinal fluid markers have been applied on cohorts of patients with Parkinsonism, with the aim to develop biomarkers for these disorders. Total tau (τΤ), phosphorylated tau at threonine 181 (τP-181) and amyloid-beta with 42 amino acids (Aβ42) are considered classical biomarkers for Alzheimer’s disease. The aim of the present study is to review the literature regarding these classical cerebrospinal fluid biomarkers in cohorts with Parkinsonism, as well as present data on novel approaches regarding analysis of these proteins.
Biomarkers, cerebrospinal fluid, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, dementia with Lewy bodies, tau protein, phosphorylated tau protein, amyloid beta
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. The pathologic hallmarks of PD are Lewy bodies, which consist of intraneuronal cytoplasmic depositions of pathological α-synuclein. Thus, PD is considered a synucleinopathy. Clinical diagnosis of PD is straightforward in typical cases. However, it can be problematic in patients with atypical clinical features. Accuracy of clinical diagnosis of PD is suboptimal, since as many as 25% of patients can be misdiagnosed.
Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) are the most common causes of atypical Parkinsonism. All of these diseases manifest with Parkinsonism, which is poorly or only transiently responsive to dopaminergic treatment.
MSA is a synucleinopathy, like PD. Its pathologic hallmark is glial cytoplasmic inclusions, which consist of abnormal α-synuclein deposition in oligodendrocytes. DLB is also a synucleinopathy, characterized by predominantly cortical Lewy bodies. PSP and CBD on the other hand are considered tauopathies, since their main pathologic findings (tufted astrocytes and astrocytic plaques, respectively) consist of abnormal tau protein aggregates in astrocytes[5,6].
Tau protein can present in six isoforms, depending on the alternate splicing of the microtubule associated protein tau (MAPT) gene. This results in the variable expression of no, one or two oligonucleotides (N1 and N2) coded by exons 2 and 3 of the MAPT gene, as well as the presence of 3-repeat (3R) or 4-repeat (4R) microtubule binding regions coded by exon 10. Depending on the predominance of 3R- or 4R-tau isoforms, tauopathies are further divided into 4R- or 3R-tauopahies. PSP and CBD are considered 4-repeat (4R) tauopathies, Alzheimer’s disease (AD) is a mixed 3R- and 4R-tauopathy, whereas Pick’s disease is a 3R-tauopathy.
Total tau protein (τT), phosphorylated tau protein at threonine 181 (τP-181) and amyloid beta with 42 amino acids (Aβ42) are well-characterized cerebrospinal fluid (CSF) biomarkers of AD. These biomarkers have been incorporated into the most recent AD diagnostic criteria and are the basis of the recently proposed AT(N) taxonomy system, which introduces biomarkers (according to their molecular specificity) for the in vivo pathological characterization of patients with AD.
The aim of this review is to present data on the utility of these three classical CSF biomarkers (τT, τP-181 and Aβ42) in the differential diagnosis of atypical Parkinsonism from PD. To this end, only studies which included patients with atypical Parkinsonism vs. PD or healthy controls are included.
This review includes representative studies which either have established our current knowledge on CSF biomarkers in Parkinsonism or provide new insights on the subject [Table 1].
Overview of the studies with data on classical CSF biomarkers in cohorts with Parkinsonism
|Studies in PSP|
|Holmberg et al.||↔||Ctrl, MSA, PD|
|Verbeek et al.||↔||Ctrl, MSA, PD|
|Aerts et al.||↔a||↓b ↑c||↔a||a. CBD, PD, ctrl
|Hall et al.||↔a ↑b||↔c||↓d||a. MSA, CBD, PD, PDD, ctrl
c. ctrl, CBD, MSA
|Schoonenboom et al.||↔||↔||↔||DLB, CBD, ctrl|
|Magdalinou et al.||↔||↔||↔||CBD, MSA, PD, ctrl|
|Constantinides et al.||↔||↔||↔||MSA, PD, CBD, ctrl|
|Noguchi et al.||↓a||↔b||↔b||a. ctrl
b. ctrl, CBD
|Wagshal et al.||↓||↓||↔||ctrl|
|Schirinzi et al.||↓||↓||↓||ctrl|
|Süssmuth et al.||↔||↔||↔||MSA, PD|
|Studies in CBD|
|Aerts et al.||↔a||↑a||↑b|
|a. ctrl, PSP, PD
c. ctrl, PSP
|Constantinides et al.||↓a||↑b ↔c||↔d||a. PD
c. PSP, MSA, PD
d. PSP, MSA, PD, ctrl
|Mitani et al.||↑||ctrl|
|Urakami et al.||↑||ctrl, PSP|
|Urakami et al.||↑||ctrl, PSP|
|Hall et al.||↔a ↑b||↑c ↔d||↔e ↑f||a. MSA, PSP, PD, PDD, ctrl
e. PSP, PD, ctrl
|Schoonenboom et al.||↓||↔||↔||ctrl|
|Magdalinou et al.||↔||↔||↔||MSA, PSP, PD, ctrl|
|Noguchi et al.||↔a ↓b||↔c||↔c||a. PSP
c. ctrl, PSP
|Studies in MSA|
|Holmberg et al.||↓||PD, PSP, ctrl|
|Shi et al.||↓a ↔b||↔c||↔c||a. ctrl
|Verbeek et al.||↔||Ctrl, PD|
|Hall et al.||↔a ↑b||↑c||↓d||a. MSA, CBD, PD, PDD, ctrl
c. PD, PDD
d. PD, ctrl
|Magdalinou et al.||↔||↔||↔||CBD, PSP, PD, ctrl|
|Constantinides et al.||↔||↔||↔||PSP, CBD, PD, ctrl|
|Süssmuth et al.||↔a||↑b||↔c||a. PD, PSP
b. ctrl, PD
c. PSP, PD, ctrl
|Mollenhauer et al.||↔||↔||PSP, PD|
|Abdo et al.||↑||ctrl|
|Herbert et al.||↑||Ctrl, PD|
|Abdo et al.||↑||PD|
|Herbert et al.||↑||PD|
|Studies in DLB|
|Schoonenboom et al.||↓a ↑b||↓b ↑a||↓b ↑a||a. ctrl
|Mollenhauer et al.||↓a ↔b||↓b ↔a||↑a||a. ctrl
|Mollenhauer et al.||↓a ↔b||↓b ↑a||↔b||a. ctrl
|Mulugeta et al.||↓a ↔b||↔c||↔c||a. ctrl
c. ctrl, PDD
|Llorens et al.||↓a||↑b||a. ctrl, PD, PDD
b. PD, MSA
|Van Steenoven et al.||↓||ctrl|
|Parnetti et al.||↓a ↔b||↓b ↑c||↓b||a. PD, PDD
|Kaerst et al.||↓||↑||PD|
|Gmitterova et al.||↓||↑||PDD|
|Gómez-Tortosa et al.||↑a ↔b||↓a ↔b||a. AD
|Boström et al.||↑a||↓a||↑b||a. AD
|Abdelnour et al.||↑||ctrl|
|Mollenhauer et al.||↔||PDD|
Most studies do not report any differences in CSF Aβ42 between PSP and other causes of Parkinsonism or controls[10-16]. Interestingly, however, some studies have reported lower Aβ42 values in PSP compared to controls[17-19]. Moreover, a single study reported lower Aβ42 levels in PSP vs. PD. According to this study, Aβ42 could differentiate PSP from PD with 83% sensitivity and 67% specificity.
Regarding CSF τT, several studies could not establish any differences between PSP patients and controls[13-17]. Likewise, no difference in τT was evident between PSP and CBD[13,15-17], MSA[13,15,16] or PD[15,16] in most studies. Two studies have supported that PSP patients exhibit lower τT levels when compared to controls[18,19], whereas a single study posited that patients with PSP have lower τT levels compared to CBD, but higher τT levels compared to PD.
Few studies include data on ratios of CSF biomarkers. In a large study, which included PSP, CBD and AD patients, elevated τP-181/Aβ42 ratio values could differentiate AD from PSP and CBD. Another study posited that lower τP-181/ τT ratio values could discriminate patients with atypical Parkinsonism (PSP and MSA) from PD. This ratio was optimal for discriminating PSP from CBD with a reported sensitivity of 86% and specificity of 75%. PSP patients could also be differentiated from controls by lower Aβ42/τT and higher τT/τP-181 ratios.
A single study examined classical CSF biomarkers in different phenotypes of PSP. To this end, patients with classic Richardson’s syndrome (RS) were compared to patients with PSP-Parkinsonism (PSP-P). Interestingly, only patients with PSP-P had elevated total τT levels, compared to RS, PD and controls. Aβ42 on the other hand was significantly lower in RS patients compared to PSP-P.
Few PSP patients seem to harbor a CSF-AD profile (generally defined as decreased Aβ42 with elevated τT or τP-181). In a large cohort, including diverse neurodegenerative disorders, 10% of PSP patients had a CSF-AD profile, as determined by an index incorporating CSF Aβ42 and τP-181 values. Likewise, only one of 19 PSP patients (~5%) had a typical CSF-AD profile, as determined by abnormal Aβ42, τT and τP-181 values, in a cohort of patients with Parkinsonism.
Lastly, the possible relationship between CSF biomarkers and clinical characteristics has also been extensively studied in PSP. Most studies agree that there is no clinical-biochemical correlation in PSP[12-15,17]. Two studies have correlated low Aβ42 levels with higher disease severity, as measured by Hoehn and Yahr score or the PSP Rating Scale.
As a general conclusion, there are no significant abnormalities in the classical CSF biomarkers in PSP. Despite being a 4R-tauopathy, CSF tau proteins do not seem to differ between PSP and other Parkinsonian disorders. CSF total tau protein, which is considered a non-specific marker of neurodegeneration, would be expected to increase in PSP, as is the case in AD. A plausible explanation would be that tau protein in PSP is concentrated intracellularly (in astrocytic plaques, tufted astrocytes and neurofibrillary tangles), and for this reason it does not enter the cerebrospinal fluid.
Additionally, no obvious clinical-biochemical correlation has been observed, while an AD biomarker profile in PSP (indicating an AD co-occurrence or possibly a PSP-like phenotype of AD) is a rarity. The presence of a CSF-AD profile in PSP patients is more likely to be indicative of the presence of dual underlying pathologies (AD and PSP), since pathological studies have not established a correlation of AD pathology and Richardson syndrome (the most common phenotype of PSP).
Most studies have focused on CSF tau proteins in CBD, since CBD is a tauopathy. Several of these studies have reported elevated levels of τT in CBD, compared to controls[12,16,21-23], PSP[12,22,23] and PD[12,13]. Interestingly, τT could differentiate CBD from PSP with 80% specificity and sensitivity in one study. Likewise, CSF τT provided 75% sensitivity and 90% specificity in the discrimination of CBD from PD in another study. However, no difference in τT between CBD and controls[14,15,17], PSP[13,15,16,20], MSA[15,16] and PD[15,16] has also been reported.
Regarding CSF τP-181, most studies did not establish any meaningful difference between CBD patients and other Parkinsonian disorders or controls[13-17]. A single study has reported elevated CSF τP-181 levels in CBD compared to PD, and another study in CBD patients compared to MSA patients.
CSF Aβ42 levels do not differ in CBD compared to other Parkinsonian disorders, according to several studies[12,13,15,17]. However, lower Aβ42 has been described in CBD patients compared to controls[14,17] and PD.
Regarding CSF biomarker indices, few studies have included relevant data in CBD. One study reported decreased Aβ42/τT ratio in CBS compared to PD and controls, whereas τP-181/τT ratio in CBS was decreased compared to controls. According to this study, τP-181/τT was optimal for PSP vs. CBD discrimination (86% sensitivity and 75% specificity). Another study posited that CBD patients have elevated τT/Aβ42 and τP-181/Aβ42 compared to PD.
Clinical and demographic data do not correlate with levels of classical CSF biomarkers in CBD, according to most relevant studies[13-15]. A single study reported that cognitive status, as measured by MMSE, correlated with both τT and τP-181 levels and was inversely correlated with Aβ42 levels. Intriguingly, τT levels in CBD and PSP were dependent on disease severity in a single study, with maximal levels in medium-stage disease.
Few studies have focused on the presence of a CSF-AD profile in cohorts of Parkinsonian disorders. According to this approach, patients are divided in those harboring a CSF-AD profile and those who do not harbor such a profile. An initial study concluded that 20% of CBS patients harbored a CSF-AD profile (as defined by τT > 400 pg/mL, Aβ42 < 400 pg/mL and τT/Aβ42 ratio > 1). In another cohort, 38% of CBS patients had a CSF-AD profile, based on an index which included τP-181 and Aβ42 values. Along the same lines, a third study posited that ~30% of CBS patients had a typical CSF-AD profile (elevated τT and τP-181 combined with decreased Aβ42). Interestingly, when patients with a CSF-AD profile were excluded from analyses, an initially reported elevated τT and decreased Aβ42 protein in CBS disappeared, and CBS patients no longer differed from PD or controls. This implied that the elevated τT and decreased Aβ42 levels in CBS might have been the result of the inclusion of AD patients who presented with a CBS phenotype. The CSF profile was implemented in another study by the same study group to investigate possible differences between AD and non-AD pathology in a CBS cohort.
In conclusion, abnormalities in classical CSF biomarkers are common in CBD. The commonly reported elevation in τT and τP-181 and decrease in Aβ42, does not seem to be a biochemical fingerprint of CBD but rather is a result of the inclusion in analyses of patients with AD pathology and a CBS phenotype. Up to 30% of CBS patients have an AD-biomarker profile, which is in accordance with pathological studies. Thus, CSF biomarkers are particularly useful tools in the in vivo discrimination of corticobasal syndrome in CBS-non-AD and CBS-AD.
An initial study on CSF Aβ42 in MSA reported lower levels compared to PD, PSP and controls. A different study group also found lower Aβ42 levels in MSA compared to controls. However, several other studies could not establish any meaningful difference in Aβ42 levels in MSA compared to other Parkinsonian disorders or controls[11,13,15,16,20,26,27].
Results regarding τT in MSA are conflicting, with most studies reporting an increase of τT in MSA compared to either controls[20,28,29] or other Parkinsonian disorders[13,20,29-31]. However, some studies have reported no difference between MSA and other Parkinsonian disorders[16,26,27], whereas a single study has supported that MSA patients exhibit lower τT compared to controls.
Few studies have included τP-181 data in the comparison of biomarkers in MSA and other Parkinsonian disorders. These studies did not find any difference in τP-181 levels in MSA compared to other study groups[15,16,20,26]. A single study has supported lower τP-181 levels in MSA compared to PD and controls.
Two studies have included CSF biomarker indices in the differential diagnosis of MSA from related disorders. More specifically, a study has supported that MSA patients have significantly lower τP-181/τT ratios compared to PD. Another study posited that higher values of τT/Aβ42 ratio could differentiate MSA from PD with high specificity but only moderate sensitivity.
Clinical-biochemical correlation studies in MSA are sparse. A study correlated disease severity in MSA with lower CSF Aβ42 levels. Another study supported that both τT and τP-181 levels increased with age in MSA. A study implementing a battery of CSF biomarkers in a cohort of diverse neurodegenerative disorders could not establish any correlation between CSF biomarkers and clinical characteristics. In conclusion, data on classical CSF biomarkers are largely inconclusive.
It is well documented that CSF Aβ42 in DLB is decreased compared to controls[14,32-36], PD[35,37,38] and parkinson’s disease dementia (PDD)[35,37,39] according to the majority of studies on the subject. Comparison of Aβ42 levels between AD and DLB has yielded conflicting results, with some studies reporting greater Aβ42 levels in DLB compared to AD[14,40,41], and other studies not reporting any significant difference between the two groups[32-34,37]. A single study reported greater Aβ42 values in DLB compared to controls and another study did not find any difference between the two groups. Another study did not report a difference between DLB and PDD.
There is consensus among studies that CSF τT is increased in AD compared to DLB[14,32,33,37,40,41]. DLB patients have been reported to harbor elevated τT levels compared to controls[14,33], although several studies could not establish any difference between DLB and controls[32,34,40]. Regarding other synucleinopathies (PD, PDD and MSA), studies have produced mixed results, reporting either an increase in τT in DLB compared to PD/PDD[35,37-39] and MSA or no difference among patient groups[34,43].
Few studies have included τP-181 in analyses of DLB cohorts. According to these limited studies, τP-181 is elevated in AD compared to DLB[14,37], although one study could not establish a difference between AD and DLB. Comparison between DLB and controls regarding τP-181 has produced mixed results, with some studies reporting an increase in τP-181 in DLB[14,32,41], whereas other studies could not establish any difference between groups. PD/PDD patients do not differ from DLB in their τP-181 profile[34,44].
Several studies in DLB, which contain longitudinal data regarding CSF biomarker level alterations over time, provide conflicting results. Two studies have reported stable Aβ42 over time in cohorts of DLB patients[39,46]. According to these studies, CSF τT and τP-181 levels either increase or decrease over time. Conversely, two other studies have provided a different profile, with unaltered τT and τP-181 levels over time, combined with a decrease in Aβ42 during the transition from prodromal to demented stage of DLB[47,48].
A CSF-AD profile (as defined by a decrease in Aβ42 and an increase in τT and/or τP-181) is common in DLB patients, presenting in 25%-50% of patients[14,42,45,49]. This profile invariably correlates with poorer prognosis[42,45]. According to a recent study, as many as 85% of DLB patients have decreased Aβ42 in CSF, either isolated (45%) or in the context of a CSF-AD profile (40%).
A single study has provided insight into the relationship between pathological finding and CSF biochemical profile. In this cohort, 72% of DLB patients had senile plaques and 50% had neurofibrillary tangles. Interestingly, there was a correlation between the presence of senile plaques and CSF Aβ42 levels. The co-occurrence of neurofibrillary tangles did not affect τT and τP-181 levels in DLB patients.
In conclusion, there is a general agreement that Aβ42 levels are decreased in DLB, either alone or accompanied by increased τT or τP-181 levels. The decrease of Aβ42 levels have been shown to correlate with faster disease progression. Decreased CSF Aβ42 levels and increased τT and τP-181 in DLB could be attributed to the frequent co-occurrence of AD pathology in patients with Lewy body disease. This hypothesis would explain the correlation of a CSF-AD profile with worse outcomes in DLB patients. Intriguingly, multiple lines of evidence suggest an interplay between α-synuclein and tau/amyloid beta aggregation, which may explain the frequent co-occurrence of AD pathology and Lewy body disease[50-52].
Most studies on classical biomarkers in atypical Parkinsonism implemented enzyme-linked immunosorbent assays (ELISAs). Advantages of ELISAs include relatively low cost, high reproducibility and high availability, since commercial ELISAs of classical CSF biomarkers are readily available. There have been efforts, however, to implement novel techniques and to target different proteins in search of new biomarkers in neurodegenerative diseases.
To this end, a study examined differences in tau isoforms in CSF, which may reflect differences in post-translational processing of tau protein. More specifically, differences in tau proteolytic products in CSF were the main study endpoint. By means of immunoprecipitation, extended (55 kDa) and truncated forms (33 kDa) of tau protein were determined in CSF. The tau 33 kDa/55 kDa ratio was significantly lower in PSP patients, compared to patients with AD, FTD, CBD, PD and DLB and emerged as a possible biomarker for PSP. The same study group replicated these results in a larger cohort. However, these promising results were not be replicated by another study group.
In another study, immuno-PCR essays were developed to measure 3R- and 4R-tau isoforms in CSF. These essays were tested in four different cohorts, which included PSP, CBD, PDD and PDD patients. The study we are referring to included four cohorts, in which the 3R and 4R-tau isoform levels varied considerably among the four cohorts (mean values in control groups ranging for both 3R- and 4R-tau from < 5 pg/mL to ~50 pg/mL). Analysis of tau isoforms in all cohorts combined indicated lower 4R-tau levels in PSP and AD. 3R-tau did not differ among study groups. The 3R-tau/τT and 3R-tau/τP-181 ratios were decreased in AD compared to PDD. The 4R-tau/τT was lower in PSP and AD compared to controls and the 4R-tau/τP-181 ratio was higher in PDD compared to PSP, CBD and AD.
Wagshal et al. developed a multitude of novel ELISAs, which target different epitopes of tau proteins, in order to examine differences in the concentration of diverse tau protein fragments in CSF. These ELISAs were applied in patients with AD, PSP and controls. Interestingly, PSP patients had lower concentrations of most tau fragments compared to controls.
Another study group implemented mass spectrometry to quantify tau-specific peptides in the entire sequence of tau protein in a cohort of PSP, AD and DLB. This novel approach yielded data for 18 tau peptides. By use of these peptides, the authors determined that the 1N and 3R-tau isoforms were mostly represented in CSF. Levels of tau peptides were intra-correlated and significantly increased in AD patients. Interestingly, AD patients had relatively decreased levels of peptides in the central core region of tau protein. This region contains phosphorylation sites, which may explain this finding.
Along the same lines, Cicognola et al. developed novel antibodies against tau fragments at amino acid 123 and 224 (tau-123 and tau-224, respectively), after having identified endogenous tau fragments ending at these amino acids. They concluded that anti-tau-224, but not anti-tau-123, was present in neurofibrillary tangles and neuropil threads of AD patients, whereas tau-224 levels were elevated in CSF of these patients and correlated with conversion from mild cognitive impairment to AD. The authors concluded that only tau-224 is neuron-specific, whereas tau-123 may represent a general non-specific marker of tau metabolism.
There has been extensive research on classical CSF biomarkers in patients with Parkinsonism, as illustrated in this review of the literature. Most studies agree that PSP patients do not exhibit a specific CSF biochemical profile. Few studies have reported decreased Aβ42 levels. A CSF-AD profile has rarely been described in PSP patients.
An elevation in CSF τT levels has been systematically reported in CBS. Moreover, few studies have also documented a decrease in Aβ42 and an increase in τP-181 in these patients. Interestingly, a significant percentage (< 40%) of CBS patients can harbor a CSF-AD profile[14,16,24]. This is in agreement with clinical-pathological studies of CBS[59-62], where AD is a relatively common underlying pathology of CBS. A study emphasized that the frequently reported elevation in CSF τT and reduction in Aβ42 in CBS might not represent an inherent biochemical characteristic of CBS and could be attributed to the inclusion of AD patients presenting with CBS. Thus, classical CSF biomarkers are particularly important in CBS cohorts, since they can indicate an underlying AD pathology.
Regarding MSA, most studies report an elevation in CSF τT protein, whereas a decrease in Aβ42 levels in MSA has been rarely reported. Although an interplay between α-synuclein and Aβ42 has been established in vitro, alterations in CSF Aβ42 levels in a synucleinopathy are difficult to explain. In a transgenic mouse model with expression of both β-amyloid peptides and synuclein, β-amyloid peptides promoted aggregation of α-synuclein. Likewise, pathological data from PD and DLB patients support the accumulation of tau oligomers in these brains. Moreover, oligomeric tau forms may co-exist in the same aggregates with α-synuclein, forming hybrid oligomers. Along the same lines, α-synuclein may induce specific toxic tau oligomers in cell cultures.
DLB patients exhibit significantly lower CSF Aβ42 values compared to other Parkinsonian disorders. Moreover, studies support that τT in DLB may be elevated. However, AD can be differentiated from DLB by means of a significant increase in τT and τP-181 in AD compared to DLB. A significant percentage of DLB patients harbor a CSF-AD profile, which indicates the frequent co-occurrence of Lewy body and AD pathologies, especially in older patients.
Classical CSF biomarkers in atypical Parkinsonism are important, particularly for the diagnostic work-up of CBS and DLB patients. A CSF-AD profile in a CBS patient indicates an underlying AD pathology. Conversely, in DLB patients, the presence of a CSF-AD profile indicates the co-occurrence of AD and Lewy body pathologies, which usually correlates with poorer prognosis. Although some differences have been reported in classical CSF biomarkers in both PSP and MSA, the results are inconsistent and require further research.
The disparity of results on classical biomarkers in atypical Parkinsonism can be largely attributed to the great heterogeneity of studies. This heterogeneity refers to diagnostic criteria, cohort synthesis, statistical analysis and pre-analytical and analytical factors. Standardization of these pre-analytical and analytical confounders, as established in recent recommendations, is paramount for more robust results. Moreover, large cohorts of Parkinsonian disorders with CSF biomarker data and pathology-confirmed diagnoses are lacking. These studies would reliably inform us on the interplay between CSF biomarkers and pathological findings. This disparity in results also illustrates the limitations of classical biomarkers in the differential diagnosis of patients with Parkinsonism, and emphasizes the need for novel approaches.
To this end, differences in isoforms of these known proteins (e.g., 3R- vs. 4R-tau protein), differences in proteolytic products and quantification of specific peptides of these proteins are promising new approaches. Moreover, better characterization of other proteins which may serve as biomarkers (such as α-synuclein or TDP-43) is of great importance.
Conception of the study, drafting of the manuscript, literature review: Constantinides VC
Conception of the study, critical appraisal of manuscript: Paraskevas GP, Boufidou F
Conception of the study, critical appraisal of manuscript, literature review: Bourbouli M, Paraskevas PG
Conception of the study, critical appraisal of manuscript: Stefanis L, Kapaki EAvailability of data and materials
Not applicable.Financial support and sponsorship
None.Conflicts of interest
All authors declared that there are no conflicts of interest.Ethical approval and consent to participate
Not applicable.Consent for publication
© The Author(s) 2020.
1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.DOIPubMed
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.DOIPubMedPMC
3. Trojanowski JQ, Revesz T; Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33:615-20.DOIPubMed
4. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.DOIPubMed
5. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-9.DOIPubMed
6. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-46.DOIPubMed
7. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989;3:519-26.DOIPubMed
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-9.DOIPubMedPMC
9. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.DOIPubMedPMC
10. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 2003;18:186-90.DOIPubMed
11. Verbeek MM, Abdo WF, De Jong D, Horstink MW, Kremer BP, et al. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Mov Disord 2004;19:238-40.DOIPubMed
12. Aerts MB, Esselink RA, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord 2011;26:169-73.DOIPubMed
13. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-52.DOIPubMed
14. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47-54.DOIPubMed
15. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015;86:1240-7.DOIPubMedPMC
16. Constantinides VC, Paraskevas GP, Emmanouilidou E, Petropoulou O, Bougea A, et al. CSF biomarkers beta-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci 2017;382:91-5.DOIPubMed
17. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005;237:61-5.DOIPubMed
18. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2015;86:244-50.DOIPubMedPMC
19. Schirinzi T, Sancesario GM, Di Lazzaro G, Scalise S, Colona VL, et al. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. J Neural Transm (Vienna) 2018;125:1373-9.DOIPubMed
20. Süssmuth SD, Uttner I, Landwehrmeyer B, Pinkhardt EH, Brettschneider J, et al. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Mov Disord 2010;25:1284-8.DOIPubMed
21. Mitani K, Furiya Y, Uchihara T, Ishii K, Yamanouchi H, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol 1998;245:44-6.DOIPubMed
22. Urakami K, Mori M, Wada K, Kowa H, Takeshima T, et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1999;259:127-9.DOIPubMed
23. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-8.DOIPubMed
24. Borroni B, Premi E, Agosti C, Alberici A, Cerini C, et al. CSF Alzheimer’s disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. J Neurol Neurosurg Psychiatry 2011;82:834-8.DOIPubMed
25. Constantinides VC, Paraskevas GP, Efthymiopoulou E, Stefanis L, Kapaki E. Clinical, neuropsychological and imaging characteristics of Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci 2019;398:142-7.DOIPubMed
26. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80.DOIPubMedPMC
27. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.DOIPubMed
28. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord 2007;13:480-2.DOIPubMed
29. Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, et al. CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 2015;6:91.DOIPubMedPMC
30. Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson’s disease. Mov Disord 2004;19:571-9.DOIPubMed
31. Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 2014;20:112-5.DOIPubMed
32. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005;19:164-70.DOIPubMed
33. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, et al. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006;44:192-5.DOIPubMed
34. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, et al. Cerebrospinal fluid levels of sappalpha and sappbeta in lewy body and Alzheimer’s disease: clinical and neurochemical correlates. Int J Alzheimers Dis 2011;2011:495025.DOIPubMedPMC
35. Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, et al. Cerebrospinal alpha-synuclein in alpha-synuclein aggregation disorders: tau/alpha-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol 2016;263:2271-7.DOIPubMed
36. van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-beta peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther 2019;11:83.DOIPubMedPMC
37. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850-5.DOIPubMed
38. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, et al. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimers Dis 2014;38:63-73.DOIPubMed
39. Gmitterova K, Gawinecka J, Llorens F, Varges D, Valkovic P, et al. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia. Eur Arch Psychiatry Clin Neurosci 2018; doi: 10.1007/s00406-018-0928-9.DOIPubMed
40. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 2003;60:1218-22.DOIPubMed
41. Boström F, Hansson O, Blennow K, Gerhardsson L, Lundh T, et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009;28:314-9.DOIPubMed
42. Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov Disord 2016;31:1203-8.DOIPubMed
43. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with lewy bodies. Neurodegener Dis 2007;4:366-75.DOIPubMed
44. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis 2013;35:137-46.DOIPubMed
45. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, et al. Cerebrospinal fluid Alzheimer’s disease biomarkers across the spectrum of lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis 2016;54:287-95.DOIPubMedPMC
46. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease. J Neural Transm (Vienna) 2005;112:933-48.DOIPubMed
47. Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, et al. Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer’s disease and dementia with lewy bodies. J Alzheimers Dis 2016;51:1069-83.DOIPubMed
48. Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, et al. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage. J Neurol Neurosurg Psychiatry 2018;89:467-75.DOIPubMed
49. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of Alzheimer biomarkers in dementia with lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.DOIPubMed
50. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A 2001;98:12245-50.DOIPubMedPMC
51. Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry 2015;78:672-83.DOIPubMed
52. Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Gerson JE, Kayed R. α-synuclein oligomers induce a unique toxic tau strain. Biol Psychiatry 2018;84:499-508.DOIPubMedPMC
53. Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 2009;30:34-40.DOIPubMed
54. Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008;71:1796-803.DOIPubMed
55. Kuiperij HB, Verbeek MM. Diagnosis of progressive supranuclear palsy: can measurement of tau forms help? Neurobiol Aging 2012;33:204.e17-8.DOIPubMed
56. Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012;123:396-405.DOIPubMed
57. Barthélemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, et al. Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis 2016;51:1033-43.DOIPubMed
58. Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. Acta Neuropathol 2019;137:279-96.DOIPubMedPMC
59. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997;236:262-4.DOIPubMed
60. Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009;24:1593-9.DOIPubMed
61. Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133:2045-57.DOIPubMed
62. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011;70:327-40.DOIPubMedPMC
63. Paik SR, Lee JH, Kim DH, Chang CS, Kim YS. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer’s disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett 1998;421:73-6.DOIPubMed
64. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.DOIPubMed
Constantinides VC, Paraskevas GP, Boufidou F, Bourbouli M, Paraskevas PG, Stefanis L, Kapaki E. Cerebrospinal fluid amyloid beta and tau proteins in atypical Parkinsonism: a review. Neuroimmunol Neuroinflammation 2020;7:120-131. http://dx.doi.org/10.20517/2347-8659.2019.22
Full-Text Views Each Month
PDF Downloads Each Month
et al., Neuroimmunology and Neuroinflammation, 2021
et al., Neuroimmunology and Neuroinflammation, 2020
et al., Neuroimmunology and Neuroinflammation, 2020
et al., Neuroimmunology and Neuroinflammation, 2020
et al., Neuroimmunology and Neuroinflammation, 2020
et al., Neuroimmunology and Neuroinflammation, 2018
et al., Neuroimmunology and Neuroinflammation, 2017
et al., Neuroimmunology and Neuroinflammation, 2017
et al., Neuroimmunology and Neuroinflammation, 2016
et al., Journal of Cancer Metastasis and Treatment, 2016